Skip to main content
KYNB
NASDAQ Life Sciences

Kyntra Bio Q2: $95.7M Cash, Roxadustat Phase 3 Start Set for 4Q

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$6.95
Mkt Cap
$28.499M
52W Low
$6.32
52W High
$12.6
52W Position info
10.0% above low
Off High info
45% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

KYNB is trading near its 52-week low of $6.32 (10.0% above the low) on light trading volume (0.2× avg).

Summary

Kyntra Bio's Q2 earnings show a $12.0M net income, $95.7M cash runway into 2028, and two pivotal clinical milestones set for Q4 2026.


Key Events · Earnings and Guidance · KYNB

  • Q2 Net Income of $12.0M

    Net income from continuing operations was $12.0 million, or $2.96 per share, compared to a net loss of $13.7 million a year ago, driven by a $30.9 million gain on deconsolidation of a subsidiary.

  • Cash Runway into 2028

    Cash, cash equivalents, investments, and accounts receivable totaled $95.7 million as of June 30, 2026, which the company expects to fund operating plans into 2028.

  • Roxadustat Phase 3 Start in 4Q 2026

    The Phase 3 protocol for roxadustat in LR-MDS with high transfusion burden has been finalized, with the goal to initiate the registrational study in the fourth quarter of 2026.

  • FG-3246 Interim Analysis in 4Q 2026

    Enrollment in the Phase 2 monotherapy trial of FG-3246 in mCRPC continues, with interim analysis on track for the fourth quarter of 2026.


Analysis · KYNB · Life Sciences

Kyntra Bio reported Q2 results with a net income of $12.0 million, driven by a $30.9 million gain on deconsolidation of a subsidiary. The company disclosed $95.7 million in cash and investments, which it expects to fund operations into 2028. Two key clinical milestones are on track for the fourth quarter: initiation of the Phase 3 roxadustat trial in LR-MDS and interim analysis of the Phase 2 FG-3246 trial in mCRPC. This provides clarity on near-term catalysts and financial runway.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KYNB was trading at $6.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.5M. The 52-week trading range was $6.32 to $12.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KYNB - Latest Insights

KYNB
Nov 16, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.00
Real-time Price: $2.91 info
Change: -$0.090 (-3%) info
Market Cap: $12.957M info
KYNB
Nov 16, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.20
Real-time Price: $2.91 info
Change: -$0.290 (-9%) info
Market Cap: $12.957M info
KYNB
Nov 16, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.20
Real-time Price: $2.91 info
Change: -$0.290 (-9%) info
Market Cap: $12.957M info
KYNB
Oct 06, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.96
Real-time Price: $2.91 info
Change: -$3.05 (-51%) info
Market Cap: $12.957M info
KYNB
Aug 31, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.65
Real-time Price: $2.91 info
Change: -$4.74 (-62%) info
Market Cap: $12.957M info